You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. CNT-Vectored Delivery of mRNA for HIV-Vaccines

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: NIAID

    Developing safe and effective preventives for HIV remains the hope for controlling the global AIDS epidemicRecentlymRNA vaccines have emerged as a promising alternative to conventional vaccine approaches because of their high potencycapacity for rapid developmentpotential for low cost manufactureTo datethere is no effective mRNA protective vaccine for HIVand the need for one is vastDespite the adv ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. FAST-CMV: A Point-of-Care Cytomegalovirus Serodiagnostic and Avidity Assy

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: NIAID

    Congenital cytomegalovirusCMVinfection is the leading cause of permanent disabilitiescognitive impairmentand sensorineural hearing loss to newbornsMaternal infections that occur during pregnancy and symptomatic congenital CMV infections have been correlated with the most severe complicationsClinical trials are currently evaluating safety and immunogenicity of diverse vaccine candidates driven by t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. SAFARI: Scalable Analysis of Firmware for AndRoid and IOS

    SBC: KRYPTOWIRE, LLC            Topic: HSB0181008

    To address the supply chain threats that stem from vulnerable or malicious software distributed through firmware on mobile and IoT devices via binary firmware images, we propose a scalable, comprehensive, and automated framework to detect firmware-borne threats, both malicious and (un)intentionally insecure, present in Android and iOS devices. We use a workflow encompassing three analysis techniqu ...

    SBIR Phase II 2019 Department of Homeland Security
  4. LMR-P25 and LTE Mission Critical Push to Talk Interface Service

    SBC: CATALYST COMMUNICATIONS TECHNOLOGIES, INC.            Topic: HSB0181005

    In Phase I, Catalyst proved the feasibility of an Interworking solution for LTE Mission Critical Push-to-Talk (MCPTT) and Land Mobile Radio (LMR) systems that meets the requirements of Public Safety as documented in the National Public Safety Telecommunications Council Public Safety LMR Interoperability with LTE Mission Critical Push to Talk report. In Phase II, we will combine innovations created ...

    SBIR Phase II 2019 Department of Homeland Security
  5. Whole-organ bioreactor with integrated nondestructive 3D molecular imaging

    SBC: Sonovol, Inc.            Topic: NHLBI

    Abstract Significance: Donor tissue shortage remains a critical problem in lung transplantation. Recent advances in tissue engineering have allowed for the possibility of generating bioengineered lungs from decellularized organ scaffolds. These scaffolds, created from the donor’s tissue, become functionalized after recellularization with a patient’s own cells. However, translation of whole-lun ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. High Throughput CRISPR/Cas9 cell line generation using the CellRaft Array

    SBC: CELL MICROSYSTEMS INC            Topic: 400

    Project SummaryGenome editing technologies, such as CRISPR/Cas9 provide a rapid, and targeted means of both knocking out gene expression and knocking in gene modifications. Since our initial Phase I submission, the utility of CRISPR technology has expanded beyond the generation of cell lines, to forward genetic screening, in vivo manipulation of gene expression and even human therapeutics. Phase I ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    PROJECT SUMMARY Glioblastoma (GBM) is an intractable cancer with an average survival time of 12 to 15 months. Treatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrier, but engineered neural stem cells (NSCs) hold great promise as GBM therapies because they selectively migrate to ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Antimicrobial and Biocompatible Endotracheal Tubes

    SBC: WYNNVISION LLC            Topic: NHLBI

    Ventilator-associated pneumonia (VAP) occurs 48–72 hours (or more) following endotracheal intubation and accounts for half of all cases of hospital-acquired pneumonia. CDC reports and many clinical studies point to a critical need for preventing ventilator associated infections rather than fighting an often losing battle against acquired infection. Responding to this unmet need, WynnVision LLC, ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Software for predicting a drug's potential to cause acute kidney injury

    SBC: DILIsym Services, Inc.            Topic: 400

    The goal of this project is to develop novel technology for predicting drug-induced kidney injury such as caused by systemic antimicrobials, diuretics, anticancer agents, and anti-inflammatory drugs. Drugs cause approximately 20 percent of community- and hospital- acquired episodes of acute renal failure, but the incidence in older adults may be as high as 60 percent. A significant problem is that ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a New Carbohydrate-based Anticoagulant Drug

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: NHLBI

    Low molecular weight heparins (LMWHs) are partially depolymerized natural products of heparin, which are isolated from porcine intestine. A worldwide distribution of contaminated heparin in 2007 was associated with 85 deaths in the US. This crisis revealed the vulnerability of the LMWH supply chain. LMWHs are complex mixtures, having average molecular masses of 3500-6000 Daltons, corresponding to ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government